Literature DB >> 34110910

Contemporary Medical Management of Peripheral Artery Disease.

Marc P Bonaca1, Naomi M Hamburg2, Mark A Creager3.   

Abstract

Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis. Modifiable risk factors including cigarette smoking, dyslipidemia, diabetes, poor diet quality, obesity, and physical inactivity, along with underlying genetic factors contribute to lower extremity atherosclerosis. Patients with PAD often have coexistent coronary or cerebrovascular disease, and increased likelihood of major adverse cardiovascular events, including myocardial infarction, stroke and cardiovascular death. Patients with PAD often have reduced walking capacity and are at risk of acute and chronic critical limb ischemia leading to major adverse limb events, such as peripheral revascularization or amputation. The presence of polyvascular disease identifies the highest risk patient group for major adverse cardiovascular events, and patients with prior critical limb ischemia, prior lower extremity revascularization, or amputation have a heightened risk of major adverse limb events. Medical therapies have demonstrated efficacy in reducing the risk of major adverse cardiovascular events and major adverse limb events, and improving function in patients with PAD by modulating key disease determining pathways including inflammation, vascular dysfunction, and metabolic disturbances. Treatment with guideline-recommended therapies, including smoking cessation, lipid lowering drugs, optimal glucose control, and antithrombotic medications lowers the incidence of major adverse cardiovascular events and major adverse limb events. Exercise training and cilostazol improve walking capacity. The heterogeneity of risk profile in patients with PAD supports a personalized approach, with consideration of treatment intensification in those at high risk of adverse events. This review highlights the medical therapies currently available to improve outcomes in patients with PAD.

Entities:  

Keywords:  amputation; exercise; incidence; myocardial infarction; peripheral artery disease

Mesh:

Substances:

Year:  2021        PMID: 34110910     DOI: 10.1161/CIRCRESAHA.121.318258

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  6 in total

Review 1.  Sex Differences in Peripheral Artery Disease.

Authors:  Maria Pabon; Susan Cheng; S Elissa Altin; Sanjum S Sethi; Michael D Nelson; Kerrie L Moreau; Naomi Hamburg; Connie N Hess
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 23.213

2.  Peripheral Vascular Disease in 2021.

Authors:  Nicholas J Leeper; Naomi M Hamburg
Journal:  Circ Res       Date:  2021-06-10       Impact factor: 23.213

Review 3.  Insulin Resistance Is Cheerfully Hitched with Hypertension.

Authors:  Susmita Sinha; Mainul Haque
Journal:  Life (Basel)       Date:  2022-04-10

4.  From Purpose to Impact: Harnessing the Elements to Improve Peripheral Artery Disease Outcomes.

Authors:  Subhash Banerjee; Lawrence Hoang; Douglas E Drachman
Journal:  J Am Heart Assoc       Date:  2022-06-20       Impact factor: 6.106

5.  Temporal trends in patients with peripheral artery disease influenced by diabetes mellitus in Germany.

Authors:  Volker H Schmitt; Lukas Hobohm; Markus Vosseler; Christoph Brochhausen; Thomas Münzel; Christine Espinola-Klein; Karsten Keller
Journal:  J Diabetes       Date:  2022-09-22       Impact factor: 4.530

6.  Resveratrol Promotes Angiogenesis in a FoxO1-Dependent Manner in Hind Limb Ischemia in Mice.

Authors:  Dongxiao Fan; Chenshu Liu; Zeling Guo; Kan Huang; Meixiu Peng; Na Li; Hengli Luo; Tengyao Wang; Zhipeng Cen; Weikang Cai; Lei Gu; Sifan Chen; Zilun Li
Journal:  Molecules       Date:  2021-12-12       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.